Patients with longer prior ET plus CDK4/6 inhibitor exposure showed the greatest benefit from elacestrant, confirming its value in endocrine-sensitive, ESR1-mutated tumors.
An expert discusses the critical need for a holistic, multidisciplinary approach to prevent and manage interconnected cardiovascular, kidney and metabolic diseases, emphasizing early identification, coordinated care teams and integrated healthcare systems to improve patient outcomes.
Among chemotherapy-naive patients, elacestrant extended median progression-free survival compared with standard therapy, particularly in ESR1-mutated cases.
An overview of the biological and clinical distinctions between hemophilia A and B, including factor deficiencies, prevalence, diagnostic nuances, and implications for treatment strategy.
An expert discusses how the “lower for longer is better” principle drives current guideline updates, with the National Lipid Association and American Diabetes Association now recommending more aggressive LDL cholesterol targets (less than 70 mg/dL for patients with diabetes) and earlier initiation of combination therapies. The recent 2025 ESC guidelines establish even lower targets, including less than 40 mg/dL for extreme-risk patients and recommend bempedoic acid as monotherapy for statin-intolerant patients or in combination therapy, with oral medications preferred before injectables.
An expert discusses how recent research surprisingly shows vitiligo lesions do not have increased skin cancer risk, fundamentally changing patient counseling from emphasizing cancer prevention to focusing on sunburn protection and addressing the profound psychosocial effects on career choices, relationships and life trajectory across all socioeconomic levels.
In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.
In this first segment from an interview with Managed Healthcare Executive about his presentation about trends in aesthetic dermatology, the 2025 Fall Clinical Dermatology Conference in Las Vegas, Mark S. Nestor, M.D., Ph.D., talks about the shift away from hyaluronic acid to collagen stimulators, such as poly-L-lactic acid.
Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.
